Ovarian Cancer Research

Ovarian cancer research and clinical trials

At City of Hope, ovarian cancer clinicians and researchers collaborate extensively to develop and evaluate new therapies for better survival and quality-of-life outcomes. Our patients have access to a wide variety of clinical trials including new chemotherapy and targeted therapies, hormone therapies, novel surgical techniques, innovative radiation approaches and new prevention strategies.

These trials give current patients access to promising, leading-edge therapies and improve overall care for future patients worldwide. Visit our clinical trials page to learn more about current studies and their eligibility criteria.

Some of our current research projects include:

  • Developing a cancer vaccine against a mutant variation of the p53 protein, which has lost the tumor suppressing ability of a normal p53 protein and instead may help ovarian and other cancers grow and spread
  • Enhancing the use of cytoreductive (debulking) surgery followed by hyperthermic intraperitoneal chemotherapy for ovarian cancer patients, including using magnetic resonance imaging to help detect and locate tumor sites before and during the surgery
  • Using adoptive T cell therapy to reprogram a patient’s immune system to recognize and attack ovarian cancer cells throughout the body.
  • Building oncolytic - or cancer-killing - viruses that can destroy ovarian cancer cells at the tumor sites and throughout the body
  • City of Hope researchers have found that a group of proteins called TWIST is responsible for ovarian cancer’s resistance against chemotherapy, and are now looking to develop drugs (TWIST inhibitors) that can overcome this defense mechanism.
  • Enhancing the quality of life for ovarian cancer patients and survivors by engaging them in a peer-to-peer support program with other survivors

Current study recruitment

City of Hope currently has a study to treat primary or recurrent carcinoma of ovarian, fallopian tube, uterine, or peritoneal origin with HIPEC after cytoreductive surgery.
 
As part of the study, Thanh H. Dellinger, M.D., and her colleagues are investigating quality of life outcomes for these patients, and the role of normothermic intraperitoneal chemotherapy following HIPEC.
 
Refer your patients for inclusion in our HIPEC study by calling 1-626-218-1133 or visit our Clinical Trials On-line and reference Procotol 12316. Visit NCT01970722 for study details.